Longer Duration of MAO-B Inhibitor Exposure is Associated with Less Clinical Decline in Parkinson’s Disease: An Analysis of NET-PD LS1

Background: Monoamine oxidase type B (MAO-B) inhibitors exhibit neuroprotective effects in preclinical models of PD but clinical trials have failed to convincingly demonstrate disease modifying benefits in PD patients. Objective: To perform a secondary analysis of NET-PD LS1 to determine if longer d...

Descrizione completa

Dettagli Bibliografici

Autori principali:	Robert A. Hauser, Ruosha Li, Adriana Pérez, Xuehan Ren, Dan Weintraub, Jordan Elm, John L. Goudreau, John C. Morgan, John Y. Fang, Michael J. Aminoff, Chadwick W. Christine, Rohit Dhall, Chizoba C. Umeh, James T. Boyd, Natividad Stover, Maureen Leehey, Richard M. Zweig, Anthony P. Nicholas, Ivan Bodis-Wollner, Allison Willis, Karl Kieburtz, Barbara C. Tilley
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	SAGE Publishing 2017-02-01
Serie:	Journal of Parkinson’s Disease
Accesso online:	https://doi.org/10.3233/JPD-160965
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!